ATX-01

DRUG2 trials

Sponsors

Arthex Biotech S.L., ARTHEx Biotech S.L.

Conditions

Myotonic Dystrophy 1Myotonic dystrophy type 1 (DM1)

Phase 1

Study of ATX-01 in Participants With DM1

RecruitingNCT06300307

ARTHEx Biotech S.L.Myotonic Dystrophy 1

Start: 2024-10-15End: 2027-07-01Target: 56Updated: 2026-02-10

A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of Intravenous Administration of ATX-01 In Male and Female Participants aged 18 to 64 with Classic Myotonic Dystrophy Type 1 (DM1)

RecruitingCTIS2023-505363-37-00

Arthex Biotech S.L.Myotonic dystrophy type 1 (DM1)

Start: 2024-08-12Target: 28Updated: 2025-08-13